[go: up one dir, main page]

WO2010151672A3 - Amino acid derived ureas - Google Patents

Amino acid derived ureas Download PDF

Info

Publication number
WO2010151672A3
WO2010151672A3 PCT/US2010/039825 US2010039825W WO2010151672A3 WO 2010151672 A3 WO2010151672 A3 WO 2010151672A3 US 2010039825 W US2010039825 W US 2010039825W WO 2010151672 A3 WO2010151672 A3 WO 2010151672A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid derived
derived ureas
ureas
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/039825
Other languages
French (fr)
Other versions
WO2010151672A2 (en
Inventor
Brent E. Korba
William C. Groutas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wichita State University
Georgetown University
Original Assignee
Wichita State University
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wichita State University, Georgetown University filed Critical Wichita State University
Publication of WO2010151672A2 publication Critical patent/WO2010151672A2/en
Publication of WO2010151672A3 publication Critical patent/WO2010151672A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel classes of amino acid derived urea compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus.
PCT/US2010/039825 2009-06-26 2010-06-24 Amino acid derived ureas Ceased WO2010151672A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22094409P 2009-06-26 2009-06-26
US61/220,944 2009-06-26

Publications (2)

Publication Number Publication Date
WO2010151672A2 WO2010151672A2 (en) 2010-12-29
WO2010151672A3 true WO2010151672A3 (en) 2011-05-12

Family

ID=43387127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039825 Ceased WO2010151672A2 (en) 2009-06-26 2010-06-24 Amino acid derived ureas

Country Status (1)

Country Link
WO (1) WO2010151672A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077914A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
US20060229294A1 (en) * 2005-02-25 2006-10-12 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing HCV infection
US20080200512A1 (en) * 2007-02-15 2008-08-21 Jeffrey Mark Blaney Hepatitis C virus polymerase inhibitors
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077914A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS
US20060229294A1 (en) * 2005-02-25 2006-10-12 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing HCV infection
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
US20080200512A1 (en) * 2007-02-15 2008-08-21 Jeffrey Mark Blaney Hepatitis C virus polymerase inhibitors
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAUD,J. ET AL.: "Potent triazoyl-proline-based inhibitors of HCV NS3 protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTER, vol. 18, 2008, pages 3400 - 3404 *

Also Published As

Publication number Publication date
WO2010151672A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2010039534A3 (en) Viral and fungal inhibitors
WO2011015656A3 (en) Composition for treating hbv infection
WO2007081974A3 (en) Viral hepatitis treatment
BR112013003101A2 (en) hepatitis c virus inhibitors
WO2010029302A3 (en) Compounds for treating viral infections
WO2011106992A8 (en) Inhibitors of hepatitis c virus ns5b polymerase
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (en) Hepatitis c virus inhibitors.
MX2011008000A (en) Cyclosporin analogues for preventing or treating hepatitis c infection.
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MX2010008749A (en) Hepatitis c virus inhibitors.
WO2008115281A3 (en) Compounds for treating viral infections
WO2008127364A3 (en) Antiviral compounds and use thereof
EA202191537A1 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2010001650A (en) Certain nitrogen containing bicyclic chemical entities for treating viral infections.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2007084435A3 (en) Methods for treating hepatitis c
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792666

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10792666

Country of ref document: EP

Kind code of ref document: A2